Combination therapy for EGFR-mutated lung cancer with lingering ctDNA
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if adding sacituzumab tirumotecan to osimertinib works better than osimertinib alone for advanced lung cancer that still shows cancer DNA (ctDNA) in the blood after initial osimertinib treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced non-squamous non-small cell lung cancer (NSCLC) with an EGFR mutation (exon 19 deletion or L858R).
- You should have completed 3 to 5 weeks of osimertinib as your first treatment without the cancer progressing, and your ctDNA test must be positive.
- You need at least one tumor that can be measured on scans.
- You must be 18 or older and have good organ function (kidneys, liver, bone marrow).
- You cannot have had prior cancer treatment for this stage except osimertinib, and no prior TROP2- or topoisomerase I-targeted therapies.
- Women of childbearing potential and men with partners must use effective contraception during and 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
This trial tests combining a targeted pill (EGFR-TKI) with an antibody drug (bevacizumab) for people with advanced non-small cell lung cancer that has a specific EGFR mutation. The goal is to see if this combination works better than the pill alone as a first treatment.
This trial tests a new combination of two drugs (BL-B01D1 and osimertinib) versus osimertinib alone as the first treatment for people with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better at stopping the cancer from growing.
This Phase 1 study tests the combination of osimertinib (a targeted lung cancer pill) with an antibody called carotuximab to treat advanced EGFR-mutated non-small cell lung cancer. It aims to see whether adding the antibody can help when the cancer has grown despite prior EGFR-targeted therapy.
This trial tests a new combination of two drugs, osimertinib and etoposide, for people with lung cancer that has not responded well to osimertinib alone. The goal is to see if adding etoposide can help stop the cancer from growing.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.